Last edition
News about "MRGPRX4 antagonist"
Incyte Acquires Escient Pharmaceuticals to Expand its Portfolio
Incyte has signed a definitive agreement with Escient Pharmaceuticals under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist.
MRGPRX4 Antagonist | 24/04/2024 | By Aishwarya | 265
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members